Natalizumab (Tysabri)
Natalizumab (Tysabri) is a medication administered by IV infusion, over one hour every four weeks, for the treatment of relapsing forms of MS. Natalizumab is theorized to block molecular interaction of alpha-4-beta-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells. The humanized monoclonal antibody binds to alpha 4/beta 1 integrin on activated lymphocytes and monocytes, and blocks leukocyte passage across the blood brain barrier.
The medication must be prescribed through the Tysabri Outreach: Unified Commitment to Health (TOUCH) program.
Additional Information
- National MS Society Tysabri
- VA Adverse Drug Events Reporting System
- VA Natalizumab (Tysabri) Criteria for Use (VA access only)
- VA Natalizumab (Tysabri) Drug Monograph (VA access only)
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
